Nayacure Labs

Company Overview

Snapshot

Founded in December 2010 by Shahar Cohen, MD, Nayacure Labs operates with 1–10 employees. The company is focused on developing regenerative medicine technologies.

Business overview

Nayacure Labs is a regenerative medicine company dedicated to restoring the function of failing body parts and enhancing human health. The company is building a pipeline of therapeutic assets, including artificial clots for localized drug delivery, organs on demand, and placental stem cell therapy for neurodegeneration. Its lead program focuses on developing personalized organs to increase transplant availability and reduce the need for immunosuppressant drugs, aiming to overcome immunological barriers in xenotransplantation and make humanized organs and composite allografts tolerable. Nayacure Labs operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the healthcare industry.

Company Intelligence Q&A

What is Nayacure Labs' primary focus?

Nayacure Labs is primarily focused on regenerative medicine, developing technologies to restore the function of failing body parts and enhance human health.

Who founded Nayacure Labs?

Nayacure Labs was founded by Shahar Cohen, MD, in December 2010.

What are Nayacure Labs' key therapeutic areas?

Nayacure Labs is developing therapeutic assets including artificial clots for localized drug delivery, organs on demand, and placental stem cell therapy for neurodegeneration.

What is Nayacure Labs' lead program?

The company's lead program is dedicated to developing personalized organs to increase the availability of organs for transplantation and reduce the need for immunosuppressant drugs.

What is Nayacure Labs' long-term goal regarding organ transplantation?

Nayacure Labs aims to overcome the immunological barrier to xenotransplantation, providing an unlimited source of humanized organs and making human-derived composite allografts tolerable.